Show
Sort by
-
Results from the phase I clinical studies evaluating Cyad-01, a first-generation NKG2D CAR T-cell product in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients
-
- Conference Paper
- C3
- open access
Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablative conditioning in relapse or refractory acute myeloid leukemia and myelodysplastic syndrome patients
-
- Conference Paper
- C3
- open access
Results from the completed dose-escalation of the hematological arm of the Phase I Think Study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapse/refractory acute myeloid leukemia and myelodysplastic syndrome patients
-
- Journal Article
- A1
- open access
Chimeric antigen receptor-T cells for targeting solid tumors : current challenges and existing strategies
-
Early signs of clinical activity in Aml patients receiving NKG2D CAR T cell therapy in the absence of pre-conditioning chemotherapy : an alternative strategy to CAR T cell therapy
-
The THINK clinical trial : preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute myeloid leukemia
-
Remissions in relapse/refractory acute myeloid leukemia patients following treatment with NKG2D CAR-T therapy without a prior preconditioning chemotherapy
-
Celyad's novel CAR T-cell therapy for solid malignancies
-
Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, Cyad-01, in acute myeloid leukemia
-
A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types